The course director of ATMRD 2023 provided perspective on the notable strides made in the movement disorder field, including the significant progress made in drug delivery. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"You don’t have to be a movement disorder neurologist, we welcome primary care physicians who see a lot of patients with neurodegenerative disorders. It’s great to come and learn about what’s new for your patients so you can refer them to these therapies."
The field of movement disorder management and therapeutics continues to evolve and change, despite the lack of disease-modifying therapies available. Over the years, advances in research has led to improvements in the understanding of the underlying biology of diseases, new capabilities in genetics, and improved approaches to diagnosis, including biomarkers and imaging. The latest innovations in the treatment of movement disorders will be presented at the upcoming Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress, held June 9-11 in Washington, DC.
The Congress is a partnership between the Parkinson & Movement Disorder Alliance (PMD Alliance) and Georgetown Medstar University Hospital, and is led by course directors Fernando Pagan, MD; and Yasar Torres-Yaghi, MD. Attendees will have the opportunity to explore in-depth therapeutics that address progressing symptoms, earn AMA PRA Category 1 credits, and connect with leaders in the field.
Prior to the meeting, Pagan and Torres-Yaghi sat down to provide insight on what clinicians can expect, as well as educational benefits non-movement disorder specialists can receive. In addition, the duo discussed the recent advances in therapeutics, including potential FDA approvals on the horizon, and ways to treat secondary symptoms of movement disorders and other related conditions.